Sugi Predict

Sugi Predict / Compounds / SCHEMBL8737804

SCHEMBL8737804

SCHEMBL8737804

Cc1cn(-c2ccc(C=O)c3c2OCO3)cn1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOA P21397 1/20 0.38
▸ MAOB P27338 1/20 0.38
▸ PSEN1 P49768 11/20 0.34
▸ PSEN2 P49810 10/20 0.34
▸ APH1B Q8WW43 10/20 0.34
▸ NCSTN Q92542 10/20 0.34
▸ APH1A Q96BI3 10/20 0.34
▸ PSENEN Q9NZ42 10/20 0.34
▸ EGLN2 Q96KS0 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ USP30 Q70CQ3 2/20 0.33
▸ CYP2E1 P05181 1/20 0.33
▸ CYP2A6 P11509 1/20 0.33
▸ KCNH2 Q12809 2/20 0.32
▸ MEN1 O00255 1/20 0.31
▸ GFER P55789 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ HKDC1 Q2TB90 1/20 0.31
▸ RXFP1 Q9HBX9 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6124673 0.81 EED (0.37) MAOAMAOBPSEN1PSEN2APH1B
SCHEMBL6124684 0.79 PSEN1 (0.34) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL6124683 0.78 PSEN1 (0.32) MAOAMAOBPSEN1PSEN2APH1B
SCHEMBL6124667 0.76 MAOA (0.38) MAOAMAOBPSEN1PSEN2APH1B
SCHEMBL9868208 0.75 EGLN2 (0.45) MAOAMAOBPSEN1PSEN2APH1B
SCHEMBL6124676 0.75 PSEN1 (0.33) MAOAMAOBPSEN1PSEN2APH1B
SCHEMBL6852501 0.72 TDP1 (0.46) ALDH1A1MAPTMEN1KMT2A
SCHEMBL6124680 0.71 MEN1 (0.35) MAOAMAOBPSEN1PSEN2APH1B
SCHEMBL6124675 0.71 CYP2E1 (0.34) MAOAMAOBPSEN1PSEN2APH1B
SCHEMBL10153121 0.70 NR2E1 (0.40) PSEN1PSEN2APH1BNCSTNAPH1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8450343-B2 Gamma secretase modulators SCHERING CORPORATION 2013-05-28 — — US disclosed
US-8450343-B2 Gamma secretase modulators SCHERING CORPORATION 2013-05-28 — — US disclosed
US-20120129846-A1 GAMMA SECRETASE MODULATORS Merck, Sharp & Dohme, Corp. 2012-05-24 — — US disclosed
US-20120129846-A1 GAMMA SECRETASE MODULATORS Merck, Sharp & Dohme, Corp. 2012-05-24 — — US disclosed
US-20110027264-A1 GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE SCHERING CORPORATION 2011-02-03 — — US disclosed
US-20110027264-A1 GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE SCHERING CORPORATION 2011-02-03 — — US disclosed
US-20110015190-A1 GAMMA SECRETASE MODULATORS SCHERING CORPORATION 2011-01-20 — — US disclosed
US-20110015190-A1 GAMMA SECRETASE MODULATORS SCHERING CORPORATION 2011-01-20 — — US disclosed
US-20100298381-A1 GAMMA SECRETASE MODULATORS SCHERING CORPORATION 2010-11-25 — — US disclosed
US-20100298381-A1 GAMMA SECRETASE MODULATORS SCHERING CORPORATION 2010-11-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120129846-A1 GAMMA SECRETASE MODULATORS BACE1, BACE2, PSEN1 MAOA 1838/4885MAOB 2160/4885PSEN1 3/4885
US-20110027264-A1 GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE BACE1, BACE2, PSEN1 MAOA 853/4885MAOB 1111/4885PSEN1 3/4885
US-20100298381-A1 GAMMA SECRETASE MODULATORS BACE1, BACE2, PSENEN MAOA 2597/4885MAOB 3153/4885PSEN1 4/4885
US-20110015190-A1 GAMMA SECRETASE MODULATORS BACE1, BACE2, PSEN1 MAOA 1887/4885MAOB 1916/4885PSEN1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.